Dr. Roychowdhury is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-6529Fax+1 614-293-9469
Summary
- Dr. Sameek Roychowdhury is an oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute. He received his medical degree from Ohio State University College of Medicine and has been in practice 11 years. He is experienced in hematologic oncology.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2008 - 2011- University of MichiganResidency, Internal Medicine, 2006 - 2008
Ohio State University College of MedicineClass of 2006
Certifications & Licensure
OH State Medical License 2012 - 2026
MI State Medical License 2006 - 2013- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing Start of enrollment: 2013 Nov 04
- Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. Start of enrollment: 2015 Feb 24
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Start of enrollment: 2020 Jan 16
Publications & Presentations
PubMed
- Myeloid neoplasm with histiocytosis and spleen tyrosine kinase fusion responds to fostamatinib.Zachary Risch, Benjamin H Kaffenberger, Catherine G Chung, Eric Samorodnitsky, Emily L Hoskins
Haematologica. 2024-11-01 - FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.Leah Stein, Karthikeyan Murugesan, Julie W Reeser, Zachary Risch, Michele R Wing
NPJ Precision Oncology. 2024-09-17 - Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.Ashish Manne, Ashwini Esnakula, Ankur Sheel, Amir Sara, Upender Manne
International Journal of Molecular Sciences. 2024-08-20
Press Mentions
Blood Test for Cancer Now Available, but Is It Ready for Prime Time?August 16th, 2022- 'Autopsy Trial' Allows Researchers to Explore How Cancer Patients' Disease Overcomes TreatmentSeptember 29th, 2021
Fibroblast Growth Factor Receptors in Cancer: Genetic Alterations, Diagnostics, Therapeutic Targets and Mechanisms of ResistanceDecember 3rd, 2020- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
